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1. Introduction 
The scientific and technological development observed since the late nineteenth century 
until nowadays has caused a significant increase in the life expectancy of the population, 
being people over 65 a significant and yearly increasing 15% of the population (Szymański 
et al., 2010). As result, the increase in the life expectancy has also increased the prevalence of 
diseases associated to ageing, especially neurodegenerative diseases such as Alzheimer's 
disease, Multiple sclerosis and Parkinson's disease (Habeck et al., 2010). These diseases, 
besides its increasing with age, are also associated to the socioeconomic status, work and 
physical activity, family history and genetic, and in the last two decades, the nutrition has 
also aroused as a relevant factor (Stampfer, 2006). In this sense, there is general consensus 
that a healthy diet may prevent the development of many diseases such as obesity, 
hypertension, diabetes mellitus, stroke, certain kinds of cancers and now neurodegenerative 
diseases (Massaro et al., 2010). Epidemiological evidences suggest that populations having a 
significant consumption of fish, a food rich in n-3 long-chain polyunsaturated fatty acids (n-
3 LCPUFA), show lower incidence of neurodegenerative diseases (Tully et al, 2003). n-3 
LCPUFA, especially docosahexaenoic acid (DHA, C22: 6 Δ 4, 7, 10, 13, 16, 19; n-3), play a 
fundamental role in the development and preservation of the nervous system, and in the 
recent years solid evidences of their involvement in the prevention and/or eventually in the 
treatment of neurodegenerative diseases have appeared (Ikemoto et al., 2001). In neuronal 
tissue DHA is found in high concentrations, especially in the phospholipids of neuronal and 
glial membranes. However, as ageing progress and during the development of 
neurodegenerative diseases, a significant reduction in the DHA content of the brain is 
produced (Tully et al., 2003), especially in the cortex, cerebellum and hypothalamus, which 
result in a considerable reduction in the fluidity of neuronal membranes and an alteration of 
the neuronal homeostasis (Sodeberg et al., 1991; Kalminj et al., 2004). Beyond the effect of 
DHA at the neuronal membranes, the fatty acid also exerts other protective effects which are 
mediated by a metabolic derivative named neuroprotectin D-1 (NPD-1) which may protect 
neurons against oxidative stress, inflammation, disruption of the cytoskeleton and from the 
activation of apoptotic signaling pathways (Bazan, 2009). NPD-1, formed from DHA, is 
normally present in the nervous system, especially in the brain, but it is especially relevant 
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in states and/or situations that may compromise the activity, integrity and neuronal 
viability, as it is the case of neurodegenerative diseases, brain injury by ischemia – 
reperfusion, leukocyte infiltration and activation of proapoptotic signaling pathways 
(Bazan, 2009; Belayev et al., 2009). In this context, NPD-1 has anti-inflammatory, 
antiapoptotic and even neuroregenerative effects, which would help to preserve in general, 
both the neuronal functioning and the nervous system (Reinoso et al 2008). A significant 
reduction of the neuronal DHA content is produced during the developing of 
neurodegenerative diseases. This reduction, which is not only produced by dietary factors, 
(i.e. low intake), it is also produced by metabolic process such as increased DHA metabolism 
and/or oxidation (Tully et al., 2003). The greatest evidence about the neuroprotective effect 
of DHA has been observed in Alzheimer's disease. DHA may suppress the cytotoxic effects 
of the accumulation of the β-amyloid peptide, being the main mechanism associated to the 
neuroprotective action of the fatty acid (Bazan, 2009; Reinoso et al., 2008). Facing this 
evidence, it is reasonable to consider the beneficial effect of increasing the consumption of 
DHA by eating foods rich in the fatty acid, such as fatty fish or DHA containing 
supplements. This chapter reviews the neuroprotective effects of DHA in the context of the 
brain ageing and some neurodegenerative diseases. It is also suggested to promote the 
consumption of food and/or supplements rich in DHA, as an effective strategy for 
preserving the brain function during ageing and especially to prevent the incidence, or to 
delay the onset of neurodegenerative diseases. 
2. DHA and brain physiology 
DHA is a LCPUFA with six double bonds, which belong to the series or family of the n-3 
polyunsaturated fatty acids (Figure 1). It is relevant that DHA is the most unsaturated fatty 
acid in our organism and is found specifically concentrated in the brain, retina and sperms 
of higher animals (Uauy et al., 2001). DHA, when provided by the diet, comes mainly from 
marine organisms such as fish (fatty or blue species), shellfish, and algae (Horrocks et al., 
2004). The first report of a deficiency of n-3 fatty acids was documented in 1982, which 
described the case of a six years girl, who received parenteral nutrition without the addition 
of n-3 fatty acids for five months after intestinal surgery (Holman et al., 1982). After the 
nutritional intervention, the girl presented low plasma DHA levels, dermatitis associated 
with neurological symptoms including neuropathy, blurred vision and psychological 
disturbances, which suggested an important role of n-3 LCPUFA, especially DHA, in the 
nervous system functions. In fact, it is now accepted that DHA is the most important n-3 
LCPUFA in the formation of neuronal plasma and synaptosomal membranes (synaptic 
vesicles), especially in the brain (McNamara & Carlson, 2006). DHA amounts approximately 
30-40% of fatty acids of the phospholipids forming the gray matter of the cerebral cortex and 
retinal photoreceptors (Carlson, 2002). The most important growing of the brain in humans 
is produced during the third trimester of fetal development and in the first two years of life. 
It is during these periods that the requirements of n-3 and n-6 LCPUFA are roused 
considerably, especially the requirements of DHA and arachidonic acid (AA, C20: 4 Δ 5, 8, 
11, 14; n-6). Animal studies have shown that the reduced availability of DHA during the 
perinatal period is associated with deficits in the establishing of neuronal networks, and  
also with multiple expressions of synaptic pathologies, including deficits in serotonin 
neurotransmission and alterations in the mesocorticolimbic dopamine pathway, 
neurocognitive deficits, and a greater anxious behavior, aggression, depression and 
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decreased visual acuity (McNamara & Carlson, 2006). Similar problems have been observed 
in preterm primates and humans, which may be reversed after n-3 LCPUFA 
supplementation. DHA intake remains also essential after the end of the brain development. 
It is required to maintain the normal brain functions, including synaptic plasticity, 
neurotransmission and visual function (McCann & Ames, 2005). 
 
21                       15                        9                         3       COOH
CH3
 
Fig. 1. Molecular structure of docosahexaenoic acid (DHA) 
3. DHA and brain metabolism 
Due to lack of enzymes necessary for neuronal de novo synthesis of DHA and AA, these 
fatty acids must be obtained preformed directly from the diet, or be synthesized from their 
precursors, α-linolenic acid (ALN, C18: 3 Δ 9, 12, 15; n-3) for DHA, and linoleic acid (LA, 
C18: 2 Δ 9, 12, n-6) for AA (Williard et al., 2001). This synthesis is carried out mainly in the 
liver and to a lesser extent in the cerebral endothelium by the astrocytes, which may export 
these fatty acids to the neurons (Lesaet al., 2003, Kalant & Cianflone, 2004). Although is still 
under discussion how these fatty acids (ALN, LA) can cross the blood-brain barrier, it has 
been demonstrated that may diffuse through the phospholipids of neuronal membranes 
(McCann & Ames, 2005). Other evidences suggest that some membrane proteins may 
facilitate the transport of ALN and/or DHA through the hematoencephalic barrier. One of 
these transporters has been identified as a caveolin binding protein type or CD36 (Williard 
et al., 2001 ; Lesa et al., 2003). However, plasma levels of LCPUFA are poorly correlated with 
the dietary intake of the precursors (Kalant & Cianflone, 2004). In fact, in healthy 
individuals, Δ5-and Δ6-desaturases, the key enzymes in the conversion process of LA to AA 
and ALN to DHA, are only induced in the absence of precursors and suppressed when the 
intake of the precursors (LA and ALN) is sufficient (Kalant & Cianflone, 2004). In contrast, 
the Δ6-desaturase activity appears to decrease with age, as has been demonstrated in rodent 
models (Cho et al, 1999; Hrelia et al., 1990). The reduction of the activity of this enzyme 
could be significantly important during ageing, considering that the elderly shows low 
tissue levels of DHA, especially when the intake of ALN is chronically low (Strokin et al., 
2006; Kalmijn et al., 1997). This situation could lead to profound alterations in the 
metabolism of the nervous system, especially in the density of the synaptosomes and/or in 
the release of neurotransmitters, as suggested from studies carried-out in the nematode 
Caenorhabditis elegans deficient for the enzyme Δ6-desaturase (Lesa et al., 2003). DHA is 
present in the phospholipids of neuronal membrane predominantly at the sn-2 position; 
therefore the incorporation of DHA in membrane phospholipids depends of the cycle 
deacylation - reacylation which occurs at the sn-2 position (Serhan et al., 2008). In rodent 
brains, this cycle has significant activity (Rapoport et al., 2001) and is dependent directly on 
the specific activities of the enzymes acyl-CoA synthetase (ACS) and phospholipase A2 
(PLA2). ACS performs the activation process by binding the fatty acid to CoA, which is an 
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ATP-dependent reaction. Once activated, the fatty acids can be incorporated into 
phospholipids. ACS isoenzymes 3, 4 and 6 are specific to LCPUFA, and in the brain the ACS 
6 isoform is specific for the acylation of DHA (Marszalek et al., 2005). At present, there is not 
sufficient background about the type of phospholipase that participate in the release of 
DHA from phospholipids. However, it has been established that in astrocytes the release of 
DHA involve a mechanism dependent of 2+Ca but independent of PLA2 (Strokin et al., 
2003). The role of PLA2 in neurons has not been clearly demonstrated, but a study in the 
hippocampus of rats, indicated that the enzyme may be of fundamental importance in the 
release of DHA in neuronal tissue (Strokin et al., 2006). Figure 2 shows a proposal of how 
DHA may be incorporated into the phospholipids of neuronal membranes. 
 
 
Fig. 2. Incorporation of DHA into the phospholipids of neuronal membranes 
4. DHA and brain ageing  
The presence of high concentrations of DHA, especially in the phospholipids of neuronal 
membranes, has been encouraged for more than 30 years the research about the roles of 
DHA in the nervous system. The evidence has demonstrated that during the embryonic 
stage and the first years of life, DHA plays a key role in the growth and development of the 
nervous and visual systems, actively participating in the processes of neurogenesis, 
neuronal migration, myelination and synaptogenesis (Uauy et al., 2001), thus directly 
impacting on cognitive development, visual, auditory, and in the memory and learning 
capabilities (McNamara & Carlson, 2006). As result of these observations, it is now strongly 
recommended to increase the consumption DHA during the pregnancy and childhood, in 
order to ensure the proper development of the nervous and visual systems (Uauy et al., 
2001). The close relationship between DHA and the developing of the nervous system, 
encouraged investigators to study what happens with this fatty acid during ageing. It was 
observed that as the individual ages, the content of DHA in neural tissue is significantly 
www.intechopen.com
 
Docosahexaenoic Acid (DHA), in the Prevention and Treatment of Neurodegenerative Diseases 
 
131 
reduced, being even greater this decrease in the population that develops 
neurodegenerative diseases (Sodeberg et al., 1991). This significant reduction may be caused 
either, by a lower intake of the fatty acid or of its metabolic precursor and/or by an 
increased in the cellular utilization of DHA (Jicha & Markesbery, 2010). DHA plays a 
relevant role in the preservation of both the histology and physiology of the neuronal tissue 
as the individual ages, by preserving the nervous system functions among which memory 
and learning are the most remarkable (Lukiw & Bazan, 2008). Several epidemiological 
studies have strongly established that a higher intake of foods rich in DHA (fatty fish 
and/or nutritional supplements based on fish oils or microalgae) is highly correlated with a 
lower risk of developing neurodegenerative diseases (Kalminj et al., 2004; Kalmijn et al., 
1997), which is also associated with a clinical history indicating that patients with 
neurodegenerative disease have significantly lower levels of DHA in plasma and brain 
(Tully et al., 2003; Sodeberg et al., 1991). 
5. Neuroprotectin D-1 and neuroprotection  
A relevant question about the attributed neuroprotective effects of DHA in ageing and 
especially against neurodegenerative diseases is referred as how this fatty acid exerts these 
effects at the molecular level. Their role in the fluidity of the neuronal membrane appears as 
one of the most relevant attributes (Saiz & Klein, 2001). In fact, up to day the classification of 
membrane fluidity is based on the level of DHA present in the phospholipids that form the 
membrane matrix (Stillwell et al., 2005). However, the higher fluidity that confers DHA to 
neuronal membrane is not sufficient to explain the neuroprotective effects attributed to the 
fatty acid. As result of multiple investigations, it has been established that acylation of DHA 
at the sn-2 position in the membrane phospholipids and the activity of PLA-2, are additional 
features of DHA, by itself, to achieve an additional neuroprotective action of the fatty acid 
against certain cytotoxic situations, as are neurodegenerative diseases (Stillwell et al., 2005; 
Brown & London, 2000). It is no casual that DHA is present mainly at the sn-2 position in the 
phospholipids of neuronal membranes (48% in phosphatidylcholine, 52% in fosfatidilserine 
and 20% in phosphatidylethanolamine) (Aveldano & Bazan, 1983). It was the discovery of a 
number of bioactive compounds derived from DHA, called protectins and resolvins, which 
show cytoprotective properties that open the way to a better understanding of how DHA 
may exert at the molecular level its neuroprotective actions (Mukherjee et al., 2004). Among 
these bioactive DHA-derivatives, NPD-1 (protectin D1 or D1 neuroprotectin: 10R, 17S-
dihydroxy-docosa-4Z, 7Z, 11E, 13E, 15Z, 19Z-hexaenoic acid), appears the most relevant 
neuroprotective agent (Serhan et al., 2008). NPD-1 is generated once DHA is released from 
the phospholipids by the hydrolytic action of PLA-2, where the enzyme 15 lipoxygenase 
initiate a complex process of lipooxidation, epoxidation and hydrolysis resulting in the 
formation of NPD-1 (Serhan, 2005). Figure 3 shows a diagram of the formation of NPD-1. 
NPD-1 may exert its neuroprotective function either through a receptor (as yet 
unidentified), which may act in an autocrine form and/or NPD-1, once formed, may be 
diffused to other neurons. The mechanisms involved in the neuroprotection afforded by 
NPD-1 may include: (i) inhibition of the expression of proinflammatory cytokines (TNFα 
and IL1β), (ii) inhibition of the generation and neurotoxicity of β-amyloid peptides and 
Ab42 (iii) increased gene expression of antiapoptotic molecules (Bcl-2 and Bcl-xL), (iv) 
reduction in the gene expression of proapoptotic molecules (Bax and Bad) and (v) increased 
neuronal antioxidant potential (Chu Chen & Bazan, 2005). Moreover, inflammatory 
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cytokines and oxidative stress may activate the synthesis of NPD-1 (Aksenov & Markesbery, 
2001). 
 
 
Fig. 3. Biosynthesis of Neuroprotectin D-1 (NPD-1) 
6. DHA and neurodegenerative diseases 
Several epidemiological, clinical and basic-experimental studies have demonstrated the 
beneficial effects of n-3 LCPUFA against various diseases, among which; cardiovascular 
disease (Hamer and Steptoe., 2006), some cancers (Gillet et al., 2011), inflammatory 
diseases such as rheumatoid arthritis (Kremer et al., 1990) and asthma (Yokoyama et al., 
2000), neurological disorders such as schizophrenia (Laugharne et al., 1996), depression 
(Hibbeln & Salem, 1995), migraine (Wagner & Nootbaar-Wagner, 1997) and 
neurodegenerative diseases such as Alzheimer's disease (Morley & Banks, 2010), Multiple 
sclerosis (Mehta et al., 2009) and Parkinson's disease (Calon & Cole, 2007). The evidence of 
the beneficial effect of DHA has been clearly demonstrated mainly in neurodegenerative 
diseases. 
6.1 DHA and Alzheimer´s disease 
Alzheimer's disease (AD) is a progressive dementia that is early manifested by the loss of 
synaptic function and memory capacity of the individual. The number of patients who are 
diagnosed the neuropathological disorder has increased substantially in all countries, 
mainly in those where has been produced an increase in the life expectancy. In fact, it is 
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estimated that about 5% of the population that borders 65 is affected by AD. The prevalence 
of the disease doubles every 5 years over 65 years (Cummings, 2004), and many studies 
suggest that almost half the population up to 85 years show symptoms related to the disease 
(Nussbaum & Ellis, 2003; Forsyth & Ritzline, 1998).The presence of the β-amyloid peptide, 
which is associated with neurotoxic effects, is one of the characteristic expression of the 
molecular damage observed in patients (Hardy & Higgins, 1992; Yankner, 1996). Its origin 
occurs from the degradation (altered or incomplete) of the β-amyloid peptide precursor 
(APP) (Selkoe, 1994). A significant reduction in DHA levels, both in erythrocytes and in the 
brain, is observed in AD, specifically in the frontal lobe, and occipital and temporal cortex 
(Guan et al., 1994). It is also produced a replacement of DHA in phospholipids by saturated 
fatty acids (SFA) among which myristic acid (14:0), palmitic (16:0) and stearic acid (18:0) are 
the most frequent (Skinner et al., 1993). Thus, it is likely that changes in the ratio AGS/n-3 
and n-6 LCPUFA could alter the neuronal function, especially at the membrane 
phospholipids, which in turn could result in neurological deficits. The altered fatty acid 
composition observed in the brains of AD patients could be caused by a deficiency in the 
LCPUFA transport from blood to the brain. It is remarkable that in patients with certain 
types of dementia or cognitive impairment it is observed the same reduction in the levels of 
n-3 LCPUFA, especially DHA (Kyle et al., 1999; Conquer et al., 2000). Interestingly, a 
decrease of DHA in plasma does not appear to be unique to AD, it is also common in the 
general cognitive impairment observed in ageing (Catalán et al., 2002). Many studies have 
demonstrated that a high intake of DHA is associated with a lower risk of AD, and in 
individuals diagnosed the disease, consumption of DHA result in a decrease in the 
progression of the characteristic symptoms, especially in relation to the cognitive 
impairment (Barberger-Gateau et al., 2002). 
6.2 DHA and multiple sclerosis 
In the case of multiple sclerosis (MS), the benefits associated with n-3 LCPUFA, especially 
DHA, have been shown in both the mental and physical disabilities. Evaluation of patients 
that has been supplemented with DHA indicates a significant improvement in the 
symptoms characteristic of the disease (Nussbaum & Ellis, 2003; Shinto et al., 2009). Some of 
these beneficial effects have been observed even in patients who consume a diet low in fat, 
but supplemented with n-3 LCPUFA of marine origin (fish oil). However, the evidence 
regarding a benefic in the progression of MS is not yet fully conclusive (Weinstock-Guttman 
et al., 2005). Considering the information currently available, it is not yet possible to 
establish a direct association between the consumption of n-3 LCPUFA and a lower 
incidence of MS, more studies are required on the issue (Weinstock-Guttman et al., 2005; 
Marcheselli et al., 2003). A study showed a relationship between reduced risk of this disease 
and the consumption of fish, but only among women (Nordvik et al., 2000). Currently, most 
hypotheses about MS suggest that n-3 LCPUFA would provide the molecules needed to 
rebuild the myelin sheath, which is severely affected in patients with this pathology. Dietary 
supplementation with n-3 LCPUFA helps to reduce the severity of MS in patients recently 
diagnosed the pathology and may delay the onset of symptoms. This is especially effective 
when supplementation is from marine oils along with vitamins and dietary professional 
counseling (Kelley, 2001). Perhaps the severity of the MS disease can be also reduced by 
modulating the immune response. Several studies have shown that a reduction in the 
dietary fat intake and changes in the relationship n-6/n-3 produce changes in the immune 
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response (Kew et al., 2003). The use of nutritional supplements rich in n-3 LCPUFA is 
associated with a reduced activity and plasma levels of circulating immune cells 
(lymphocytes, polymorph nuclear neutrophils and monocytes), including the reduction in 
the production of inflammatory mediators (Weinstock-Guttman et al., 2005; Nordvik et al., 
2000). Moreover, a reduction in the intake of n-3 LCPUFA improves a number of indexes 
associated with the immune response, including lymphocyte proliferation, increased 
macrophage activity and cytokine production (Serhan et al., 2000). These records allow the 
suggestion of a protective role of n-3 LCPUFA in MS, which would lead to establish the 
potential of the use of n-3 LCPUFA as anti-inflammatory and neuroprotective in MS, 
although it remains a topic for further research. 
6.3 DHA and Parkinson´s disease  
In contrast to AD, the relationship of fat intake and the risk of developing Parkinson's 
disease (PD) is very limited. Two studies have only established an association between high 
consumption of saturated fatty acids, low intake of n-3 LCPUFA and the increased of the 
risk to develop PD (Chen et al., 2003; de Lau et al., 2005). To date researchers have not been 
able to establish a direct association between low intake of n-3 LCPUFA and increased risk 
of developing PD. However, as in patients with AD, in the brains of people with PD it is also 
observed a significant decrease in the levels of n-3 LCPUFA, especially DHA (Johnson et al., 
1999). Research in primates allow to observe a significant reduction in the extent of 
levodopa-induced dyskinesia (a damage model for the PD) in animals supplemented with 
DHA, which suggests that these effects would be mediated by the activation of retinoid X 
receptors (RXR) (Samadi et al., 2006). In addition, data from these investigations show a 
drastic drop in neural DHA levels (Julien et al., 2006; Breckenridge et al., 1973). Also, the 
dietary supplementation with DHA of animals reduced the neuronal damage produced by a 
characteristic PD-inducer agent, the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP) (Bousquet et al., 2008). Currently, the available information is not sufficient to 
establish a neuroprotective effect of DHA in the development of PD, being necessary to 
carry out more studies on the subject. 
7. Dietary sources and intake of DHA 
The metabolic precursor of n-3 LCPUFA, ALA, is found almost exclusively in land-based 
plant foods, such as nuts (walnuts 6%), chia seeds (Salvia hispanica) and flax seeds (Linum 
usitatissimum) and in some edible oils, such as soy (7 %), canola (11%), evening primrose 
(27%), chia (58%) and clary sage (60%). While, the already-formed DHA is found exclusively 
in marine foods, either of animal or vegetal origin, especially in fatty fish such as tuna, 
mackerel, menhaden, salmon, and some algae and microalgae. Unfortunately, the western 
consumption of ALA and DHA is very low, which has forced the development of 
nutritional supplements rich in DHA either from fish oils or microalgae, and also to add this 
fatty acid to foods such as vegetable oils, milk and derivatives. In this regard, in addition to 
the capsules containing fish oil or DHA concentrates which are very popular and available 
DHA can be also added to various foods such as dairy, dairy products, juices, beverages, 
bakery products, etc. The fatty acid may be provided in the form of triglycerides, 
phospholipids, and in pure form as ethyl esters (Valenzuela et al., 2006). Today, a wide 
variety of foods containing DHA are available from the retail and nutraceutical market. 
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8. Conclusion and perspectives 
Neurodegenerative diseases may significantly alter the functioning of the nervous system, 
reducing both the number and function of neurons, which seriously affects the quality of life 
for those suffering these diseases. New strategies aiming to the prevention and/or the 
treatment of these diseases are of high priority. In this context DHA and its derivative NPD-
1, emerged as a new perspective for the prevention and/or therapeutic management of 
these diseases, especially considering the social and economic devastation that neurological 
diseases may produce to the individual and the family. Future clinical research and 
nutritional interventions should be planned directly to establish the necessary doses of DHA 
needed to achieve significant beneficial effects, as well as to encourage the development and 
consumption of foods and/or supplements rich in this fatty acid. In this regard, the 
development of functional foods and/or nutraceuticals containing DHA at different 
concentrations is an alternative that the pharmaceutical and the food industries should 
consider very seriously (Valenzuela et al., 2009). To day the increase of the consumption of 
fish or seafood appear as not entirely feasible, due to the massive depredation of the 
resource, which has decreased its availability and consequently has increased the price of 
the products from the sea. Perhaps, in the future the increasing activity of the aquaculture 
may offer a viable alternative to improve the general consumption of n-3 LCPUFA to the 
western population and helping to prevent the early onset of neurodegenerative diseases. 
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